Brief Title
Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107
Official Title
Additional Circulating Markers of Angiogenesis and Disease in Mesothelioma Patients Treated on CALGB 30107
Brief Summary
RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the
laboratory may help doctors learn more about cancer and identify biomarkers related to
cancer.
PURPOSE: This laboratory study is looking at biomarkers of angiogenesis and disease in
patients with unresectable malignant mesothelioma treated on clinical trial CALGB-30107.
Detailed Description
OBJECTIVES:
- Determine if elevated levels of thrombospondin I serum levels, vascular endothelial
growth factor receptor I, fibroblast growth factor, transforming growth factor, and
mesothelin portend a poor prognosis in patients with unresectable malignant mesothelioma
treated with vatalanib on protocol CALGB-30107.
- Determine if elevated levels of thrombospondin I serum levels, vascular endothelial
growth factor receptor I, fibroblast growth factor, transforming growth factor, and
mesothelin correlate with response or stable disease in these patients.
OUTLINE: Serum samples previously obtained from patients on protocol CALGB-30107 are tested
for levels of thrombospondin I serum, vascular endothelial growth factor receptor I,
fibroblast growth factor, transforming growth factor, and mesothelin using enzyme-linked
immunosorbent assays (ELISA).
PROJECTED ACCRUAL: A total of 47 specimens will be accrued for this study.
Study Type
Observational
Primary Outcome
Level of biomarkers, including thrombospondin I, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin (high vs low)
Secondary Outcome
Effect of biomarker expression level on overall survival
Condition
Malignant Mesothelioma
Intervention
immunoenzyme technique
Study Arms / Comparison Groups
Group 1
Description: Serum samples previously obtained from patients on protocol CALGB-30107 are tested for levels of thrombospondin I serum, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin using enzyme-linked immunosorbent assays (ELISA).
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Other
Estimated Enrollment
47
Start Date
November 2005
Completion Date
August 2015
Primary Completion Date
March 2006
Eligibility Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of malignant mesothelioma
- Unresectable disease
- Must have received treatment with vatalanib on protocol CALGB-30107
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Robert A. Kratzke, MD, ,
Administrative Informations
NCT ID
NCT00898547
Organization ID
CALGB-150509
Secondary IDs
U10CA031946
Responsible Party
Sponsor
Study Sponsor
Alliance for Clinical Trials in Oncology
Collaborators
National Cancer Institute (NCI)
Study Sponsor
Robert A. Kratzke, MD, Study Chair, Masonic Cancer Center, University of Minnesota
Verification Date
January 2019